Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.56 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.39 |
| ▸ | JAK1 known ✓ | P23458 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587010 | 0.98 | ROCK2 (0.58) | ROCK2ROCK1TDP1SIRT3CYP11B2 | |
| SCHEMBL30465597 | 0.98 | ROCK2 (0.58) | ROCK2ROCK1TDP1SIRT3CYP11B2 | |
| Hydrochloric Acid SCHEMBL17143441 | 0.83 | ROCK2 (0.56) | ROCK2ROCK1TDP1SIRT3GAA | |
| Hydrochloric Acid SCHEMBL1942270 | 0.83 | ROCK2 (0.56) | ROCK2ROCK1TDP1SIRT3GAA | |
| Hydrochloric Acid SCHEMBL2841145 | 0.83 | GAA (0.43) | ROCK2ROCK1TDP1SIRT3CYP11B2 | |
| Hydrochloric Acid SCHEMBL17318497 | 0.82 | ROCK2 (0.59) | ROCK2ROCK1TDP1SIRT3CYP11B2 | |
| SCHEMBL1027774 | 0.81 | GAA (0.45) | ROCK2ROCK1TDP1SIRT3CYP11B2 | |
| SCHEMBL15514423 | 0.81 | ROCK2 (0.58) | ROCK2ROCK1TDP1SIRT3CYP11B2 | |
| SCHEMBL29574646 | 0.81 | ROCK2 (0.58) | ROCK2ROCK1TDP1SIRT3GAA | |
| SCHEMBL7533 | 0.81 | ROCK2 (0.58) | ROCK2ROCK1TDP1SIRT3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630550-B2 | Pharmacophore for trail induction | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4470617-A2 | PHARMACOPHORE FOR TRAIL INDUCTION | The Scripps Research Institute (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3662910-B1 | PHARMACOPHORE FOR TRAIL INDUCTION | SCRIPPS RESEARCH INST (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240190877-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-13 | — | — | US | disclosed |
| US-11891392-B2 | Pharmacophore for trail induction | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-06 | — | — | US | disclosed |
| CN-111499636-B | Pharmacophores for TRAIL induction | 斯克里普斯研究学院（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220002300-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-06 | — | — | US | disclosed |
| US-20200283440-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-09-10 | — | — | US | disclosed |
| CN-111499636-A | Pharmacophores for TRAI L induction | 斯克里普斯研究学院 | 2020-08-07 | — | — | CN | disclosed |
| EP-3662910-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | The Scripps Research Institute (US) | 2020-06-10 | — | — | EP | disclosed |
| US-7553854-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| CN-101432281-A | 6-O-substituted benzoxazole and benzothiazole compounds and methods for inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2009-05-13 | — | — | CN | disclosed |
| EP-2010528-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | Novartis Pharma AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| WO-2007121484-A2 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| US-20070219215-A1 | Thioamides and Salts Thereof and Cytokine Production Inhibitors Containing Both | ISHIHARA SANGYO KAISHA, LTD (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1716851-A1 | THIOAMIDES AND SALTS THEREOF AND CYTOKINE PRODUCTION INHIBITORS CONTAINING BOTH | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630550-B2 | Pharmacophore for trail induction | STAT3, STAT1, STAT4 | ROCK2 2057/4885ROCK1 2381/4885JAK2 98/4885 |
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | ROCK2 102/4885ROCK1 53/4885JAK2 1655/4885 |
| US-20070219215-A1 | Thioamides and Salts Thereof and Cytokine Production Inhibitors Containing Both | IFNG, TST, STAT6 | ROCK2 3692/4885ROCK1 3486/4885JAK2 22/4885 |
| US-20220002300-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | AIFM1, TNFRSF1A, TNFSF10 | ROCK2 3621/4885ROCK1 3611/4885JAK2 3294/4885 |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | CSF1R, CSF3R, FLT3 | ROCK2 2104/4885ROCK1 1227/4885JAK2 56/4885 |
| US-11891392-B2 | Pharmacophore for trail induction | AIFM1, TNFRSF1A, TNFSF10 | ROCK2 3621/4885ROCK1 3611/4885JAK2 3294/4885 |
| US-20240190877-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | AIFM1, TNFRSF1A, TNFSF10 | ROCK2 3621/4885ROCK1 3611/4885JAK2 3294/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | ROCK2 1054/4885ROCK1 421/4885JAK2 610/4885 |
| US-20200283440-A1 | PHARMACOPHORE FOR TRAIL INDUCTION | AIFM1, TNFRSF1A, TNFSF10 | ROCK2 3621/4885ROCK1 3611/4885JAK2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.